Pharmafile Logo
Pharmafocus logo
Advanced Search

Medical Communications

Showing 15 posts of 6408 posts found.

lab

Eisai partners with Novartis in renal cell carcinoma collaboration

June 3, 2016 Medical Communications, Sales and Marketing Afinitor, Eisai, Lenvima, Novartis, US, everolimus, lenvatinib mesylate

Eisai (TYO: 4523) has announced that it has entered into a partnership with Novartis Pharmaceuticals to collaborate on commercial and …
News

Bayer, Orion to start Phase III trials for prostate cancer drug

June 3, 2016 Medical Communications, Research and Development, Sales and Marketing Bayer, drug trial, orion, prostate cancer, research

German pharma and crop sciences giant Bayer (ETR: BAYN) and Orion Corp (Nasdaq Helsinki: ORNAV) have agreed to start a Phase …
News

New FDA expanded access guidelines spell trouble for Sarepta

June 2, 2016 Medical Communications, Research and Development, Sales and Marketing Duchenne Muscular Dystrophy, Eteplirsen, FDA, compassionate grounds, sarepta

New guidelines intended to streamline the process of expanded access to medicines by the US Food and Drug Administration (FDA) …
News
janssen_latest_logo_on_sign_closer

Janssen says its Trevicta gets European regulatory approval as maintenance therapy for Schizophrenia

June 2, 2016 Medical Communications, Research and Development European Commission, Janssen, Trevicta, schizophrenia

Janssen said the European Commission has approved its Trevicta (paliperidone palmitate, a 3‑monthly injection) as maintenance treatment of schizophrenia.  Trevicta …
News

Nice rejects Janssen’s Imbruvica in draft guidance

June 1, 2016 Medical Communications, Research and Development

The UK regulators have not recommended Janssen’s leukaemia drug Imbruvica (ibrutinib) to treat in draft guidance. The National Institute for …
News
biogen_idec_hillerod_2008

Biogen says European regulatory committee adopts positive view for Tysabri

June 1, 2016 Medical Communications, Research and Development, Sales and Marketing Biogen, CHMP, EMA, Tysabri, multiple sclerosis

Biogen (Nasdaq: BIIB) said the European regulatory committee has backed the approval of a variation to the marketing authorization for its …
News
teva_copy

FDA asks Teva for further study on Huntington drug candidate

June 1, 2016 Medical Communications, Research and Development Huntington disease, Teva, US FDA, regulation

Israel-based Teva Pharmaceutical Industries (NYSE: TEVA) said the US regulators have put on hold the approval for its drug to …
News
frank_armstrong_chairman

Uni spin out gets new chariman, CFO, COO

May 27, 2016 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Caldan Therapeutics is a spin-out company from the Universities of Glasgow and Southern Denmark which is looking at developing novel …
Appointment
clinical_trial_3

EMA to revise clinical trial guidelines

May 27, 2016 Medical Communications, Research and Development EMA, Guidelines, amend, clinical trial, review, revise

The European Medicines Agency (EMA) has announced that it will conduct a review in an attempt to revise its guidelines …
News
shire_image_4

Shire gets positive opinion from EMA on rare gastrointestinal disease treatment

May 27, 2016 Medical Communications, Research and Development, Sales and Marketing CHMP, EMA, Revestive, Shire, gastrointestinal, paediatric, short bowel syndrome, treatment

Shire (LSE: SHP) has announced that it has received a positive opinion from the European Medicines Agency’s (EMA) Committee for …
News
roche__tree

Roche says comparison study for its Gazyva/ Gazyvaro showed superior progression-free survival in follicular lymphoma

May 27, 2016 Medical Communications, Research and Development Comparison Study, Roche, drug trial, follicular lymphoma

Roche (SIX: ROG) on Friday said late-stage comparison trials for its drug to treat a slower form of non-Hodgkin lymphoma …
News

AstraZeneca says NDA for drug to treat hyperkalaemia gets observations from the US FDA

May 27, 2016 Medical Communications, Research and Development AstraZeneca, NDA, US FDA, regulation

UK pharma firm AstraZeneca (LSE: AZN) on Friday said the US Food and Drug Administration (FDA) has issued a complete …
News

FDA approves first buprenorphine implant for opioid dependence

May 27, 2016 Medical Communications, Sales and Marketing FDA, addiction, buprenorphine, dependence, implant, opioid, probuphine

The US Food and Drug Administration (FDA) has approved Probuphine, which is the first buprenorphine implant for the maintenance treatment …
News

AstraZeneca says its Faslodex shows superiority in comparison study for advanced breast cancer

May 27, 2016 Medical Communications, Research and Development, Sales and Marketing AstraZeneca, breast cancer, comparision study, drug trial

UK drugmaker AstraZeneca (LSE: AZN) on Friday said late-stage comparison trials for its drug to treat advanced breast cancer showed …
News
sanofi_hq__boetie_hall

Sanofi makes move to remove Medivation board; Medivation hits back

May 25, 2016 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Medivation, Sanofi, removal of board, takeover

Sanofi (NYSE: SNY) has taken their proposed takeover of Medivation (NASDAQ: MDVN) up several notches, with the French company filing …
News
The Gateway to Local Adoption Series

Latest content

Rhythm AI’s STAR Apollo system receives FDA clearance for atrial fibrillation

February 12, 2026

iOrganBio appoints Karol Jarzabek as Chief Operating Officer

February 12, 2026

Ensera Design expands UK leadership team with new senior appointments

February 11, 2026

Infinitopes announces $15.4m in additional seed funding to advance cancer vaccine

February 11, 2026

Angelini Pharma appoints Roberto Scrivo as Chief of External Affairs, Communication and Sustainability Officer

February 10, 2026